Member has chosen to not make this information public.


Member not yet following any Groups.

Posts (24)

Mon, Jan 20 9:44pm · Mayo Clinic launches Vancomycin clinical trial for Primary Sclerosing Cholangitis in Primary Sclerosing Cholangitis (PSC)

2019-01-14 PSC Clinical Trial

Mayo Clinic in Minnesota, Arizona and Florida is currently conducting a randomized placebo controlled clinical trial, examining the impact of oral vancomycin on markers of cholestasis among patients with PSC. The treatment period is approximately 18 months and requires about five clinic visits along with lab draws at home.

Please contact Mr. Mitch Clayton (study coordinator) at 507-284-2698 or clayton.mitchell@mayo.edu for additional details.

A link to the study on clinicaltrials.gov is provided below:


Dec 30, 2019 · Liver Stiffness is Associated with PSC Outcomes in Primary Sclerosing Cholangitis (PSC)

20919-01-31 Liver Elastography
In a recent paper, published in the Journal Clinical Gastroenterology and Hepatology, Eaton et al., found that measuring liver stiffness of patients suffering from PSC is associated with outcomes of the disease. “Monitoring liver stiffness with magnetic resonance elastography has prognostic value. Both baseline liver stiffness and changes in liver stiffness over time are associated with hepatic decompensation (i.e., failure of the liver). However, changes in liver stiffness are typically slow to occur unless advanced fibrosis is already present” Dr. Eaton said. This is the largest study of magnetic resonance elastography on PSC patients and introduces the utility of such non-invasive testing in future clinical trials of these patients.
Read the paper  from Dr. Eaton

Dec 16, 2019 · Statin Use and PSC in Primary Sclerosing Cholangitis (PSC)

2019-01-21 Statins PSC
In a recent paper published in the journal Clinical Gastroenterology and Hepatology,  Stokkeland K. et al., reported the effects of exposure to medications on the outcomes of PSC using a population-based cohort of 2,914 patients from Sweden. The authors found that use of statins or azathioprine, among patients with PSC, was associated with reduced risk of all cause mortality, death or liver transplantation. Of note, exposure to ursodeoxycholic acid did not affect the mortality of these patients. Despite the retrospective nature of this study, these interesting findings suggest pursuing further investigation on the role of statins in the outcomes of PSC.

Dec 2, 2019 · Coping Needs of Children with Primary Sclerosing Cholangitis in Primary Sclerosing Cholangitis (PSC)

2019-01-14 PSC Child

Primary Sclerosing Cholangitis (PSC) is a slowly progressing disease that affects both adults and children. Several of the clinical features of the disease are different between pediatric and adult patients. Importantly, the coping elements of the disease in children and their families are unique.

In this presentation, Dr. Mounif El-Youssef, an Associate Professor of Medicine and a Pediatric Hepatologist from Mayo Clinic, discusses the coping needs of a child diagnosed with PSC.

View the full presentation from Dr. El-Youssef.

Nov 18, 2019 · An Overview of Primary Sclerosing Cholangitis in Primary Sclerosing Cholangitis (PSC)

2019-01-16 PSC Liver

Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that affects about 1 in 10,000 people.

In this presentation, Robert C. Huebert, M.D, an Associate Professor of Medicine and transplant Hepatologist from Mayo Clinic, provides a great overview of PSC, including promising approaches of regenerative medicine to treat the disease.

View the full presentation from Dr. Huebert.

Nov 4, 2019 · Bile Acid Profiles in Primary Sclerosing Cholangitis Predict Advancement of Disease in Primary Sclerosing Cholangitis (PSC)

2019-11-19 Artificial Intelligience

Meaningful and reliable predictors of disease progression in PSC are currently lacking despite efforts over the past three decades. Patients with PSC often demonstrate increased plasma bile acids (BA) concentrations due to ongoing cholestasis, a hallmark of the disease. However, the relationship between composition of the BA in blood and future development of advanced liver disease among patients with PSC remains unclear. In fact, an assessment of plasma BA as predictors of clinical progression in PSC has not been demonstrated. In our present study presented by Omar Mouse MD, et al., at the 2019 Annual conference of the American Associations for the Study of Liver Diseases (AASLD) we use machine learning, an artificial intelligence application, to establish a non-invasive, reliable BA-based model, that is predictive of events of liver disease advancement. More than 400 PSC patients participated from across the US and 108 patients with PSC from Norway were included to make this study possible. Our BA-based model could be useful in PSC prognostication and stratification into clinical trials.

Read the full abstracts from the PSC team

Oct 21, 2019 · Understanding the Mechanism of Aging Cholangiocytes in PSC in Primary Sclerosing Cholangitis (PSC)


Aging (senescent) bile duct cells , i.e., cholangiocytes, demonstrate an arrest of the cell cycle, hypersecretion of inflammatory molecules and resistance to cell death. O’Hara et al., previously reported that aging of cholangiocytes is a feature in PSC patients, and that this event is regulated by a central molecular pathway (Ras signaling) as well as the transcription factor, ETS1. In a recently published manuscript, his team further explored the molecular mechanisms regulating senescent cholangiocyte resistance to cell death. Using PSC patients derived tissues and an inducible cell culture model of cholangiocyte senescence, O’Hara et al., reported that the transcription factor, ETS1, interacts with a chromatin modifying enzyme, called p300, to induce the expression of a pro-survival protein, BCL-xL, which in turn promotes senescent cholangiocyte resistance to cell death. These new exciting data suggest that ETS1 is a central regulator of the senescent cholangiocyte phenotype. This novel knowledge provides the basis for exploring new targets for the therapeutic removal of aging cholangiocyte as an approach to treat PSC.

Read the full abstract from the PSC team.

Sep 23, 2019 · Biochemical and Imaging Biomarkers in PSC in Primary Sclerosing Cholangitis (PSC)

biomarker test

Primary Sclerosing Cholangitis (PSC) is a slowly progressing liver disease that lacks an ideal biomarker, which could predict disease progression. A biomarker is a measurable indicator of the presence or severity of a disease state. For example, body temperature is a biomarker of fever.

In this presentation, Dr. John Eaton, an Assistant Professor of Medicine and transplant Hepatologist from Mayo Clinic, discusses in detail the importance, current biomarkers of, and ongoing approaches to develop novel biomarkers for PSC.

View the full presentation from Dr. Eaton.